Literature DB >> 6658902

Mechanisms of the contractile effect induced by uridine 5-triphosphate in canine cerebral arteries.

Y Shirasawa, R P White, J T Robertson.   

Abstract

This study was performed to elucidate mechanisms responsible for the contraction of isolated canine cerebral arteries induced by uridine 5'-triphosphate (UTP) and to ascertain whether UTP given intracisternally causes cerebral arterial constriction. The latter was proven arteriographically to be the case. In vitro, UTP (10(-4)M) and UDP were similar in potency, produced sustained contractions, and were more effective than other pyrimidine nucleotides or uridine. Unlike serotonin (5-HT), UTP was not antagonized by cinanserin and failed to cause constriction of mesenteric arteries. Adenosine similarly antagonized 5-HT and UTP. The Ca2+ antagonist nimodipine abolished contractions caused by high K+ but only incompletely antagonized 5-HT or UTP. On the other hand, procedures that hyperpolarize the cell membrane (low K+ followed by K+) abolished tonic contractions induced by UTP. Hyperpolarization prior to UTP (with or without nimodipine) did not, however, prevent the occurrence of a phasic contraction. Papaverine or lanthanum antagonized this phasic response. It was concluded that UTP selectively affects cerebral arteries, may initiate contraction by releasing membrane bound Ca2+, depolarizes the cell membrane to open receptor operated and potential sensitive calcium channels, but does not inhibit the electrogenic Na-pump nor specifically antagonize the vasodilator adenosine.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6658902     DOI: 10.1161/01.str.14.3.347

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  9 in total

1.  Purinergic receptors regulate myogenic tone in cerebral parenchymal arterioles.

Authors:  Joseph E Brayden; Yao Li; Matthew J Tavares
Journal:  J Cereb Blood Flow Metab       Date:  2012-11-21       Impact factor: 6.200

2.  Evidence for two separate vasoconstriction-mediating nucleotide receptors, both distinct from the P2x-receptor, in rabbit basilar artery: a receptor for pyrimidine nucleotides and a receptor for purine nucleotides.

Authors:  I von Kügelgen; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-06       Impact factor: 3.000

3.  Evidence for the expression of multiple uracil nucleotide-stimulated P2 receptors coupled to smooth muscle contraction in porcine isolated arteries.

Authors:  S J Rayment; M L Latif; V Ralevic; S P H Alexander
Journal:  Br J Pharmacol       Date:  2007-01-29       Impact factor: 8.739

4.  Activation of NADPH oxidase by purine and pyrimidine nucleotides involves G proteins and is potentiated by chemotactic peptides.

Authors:  R Seifert; R Burde; G Schultz
Journal:  Biochem J       Date:  1989-05-01       Impact factor: 3.857

5.  Evidence for a P2-purinoceptor mediating vasoconstriction by UTP, ATP and related nucleotides in the isolated pulmonary vascular bed of the rat.

Authors:  A Rubino; G Burnstock
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

6.  Evidence for a vasoconstriction-mediating receptor for UTP, distinct from the P2 purinoceptor, in rabbit ear artery.

Authors:  I von Kügelgen; D Häussinger; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-11       Impact factor: 3.000

7.  Dual regulation of cerebrovascular tone by UTP: P2U receptor-mediated contraction and endothelium-dependent relaxation.

Authors:  Y Miyagi; S Kobayashi; J Nishimura; M Fukui; H Kanaide
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

8.  Mechanism of asynchronous Ca(2+) waves underlying agonist-induced contraction in the rat basilar artery.

Authors:  H T Syyong; H H C Yang; G Trinh; C Cheung; K H Kuo; C van Breemen
Journal:  Br J Pharmacol       Date:  2009-01-16       Impact factor: 8.739

9.  Potent P2Y6 receptor mediated contractions in human cerebral arteries.

Authors:  Malin Malmsjö; Mingyan Hou; William Pendergast; David Erlinge; Lars Edvinsson
Journal:  BMC Pharmacol       Date:  2003-05-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.